Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 921-928

  Prevrhal, Sven ^a   Krege, John H ^b   Chen, Peiqi ^b   Genant, Harry ^a,c   Black, Dennis M ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c SYNARC INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fracture risk; Quantitative morphometry; Semiquantitative; Teriparatide; Vertebral

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; VITAMIN D;

ARTICLE; BODY HEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK REDUCTION; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; POSTMENOPAUSE; RISK; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX; SPINAL FRACTURES; SPINE; TERIPARATIDE;

EID: 67649382241     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902790993     Document Type: Article

References (44)

1. Genant HK, Jergas M, Van Kuijk C, eds. Vertebral fracture in osteoporosis. Radiology Research and Education Foundation, San Francisco, CA, USA, 1995
2. Black DM, Palermo L, Nevitt MC, et al. Defining incident vertebral deformity: a prospective comparison of several approaches. J Bone Mineral Res 1999;14:90-101 (Pubitemid 29021608)
3. Leidig-Bruckner G, Genant HK, Minne HW, et al. Comparison of a semiquantitative and a quantitative method for assessing vertebral fractures in osteoporosis. Osteoporos Int 1994;4:154-161 (Pubitemid 24163548)
4. Wu CY, Li J, Jergas M, et al. Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 1995;5:354-370
5. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996;11:984-996
6. Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994;79:1595-1599
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541 (Pubitemid 26411651)
8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645 (Pubitemid 29384151)
9. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352 (Pubitemid 29483192)
10. Chesnut 3rd CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276
11. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91 (Pubitemid 30099515)
12. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249 (Pubitemid 41094364)
13. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468 (Pubitemid 38133766)
14. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822
15. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23:81
16. Silverman SL, Christiansen C, Genant HK, etal. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Mineral Res 2008, DOI: 10. 1359/jbmr.080710
17. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708
18. Black DM, Palermo L, Nevitt MC, et al. Comparisons of methods for defining prevalent vertebral fractures: the Study of Osteoporotic Fractures. J Bone Mineral Res 1995;10:890-902
19. Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-1148 (Pubitemid 23261108)
20. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
21. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-2030 (Pubitemid 39390560)
22. Black DM, Cummings SR, Stone K, et al. A new approach to defining normal vertebral dimensions. J Bone Miner Res 1991;6:883-892
23. Efron B, Tibshirani RJ An introduction to the bootstrap. Monographs on Statistics and Applied Probability. New York: Chapman & Hall, 1993:57
24. McCloskey EV, Vasireddy S, Threlkeld J, et al. Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis. J Bone Miner Res 2008;23:1561-1568
25. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 2000;11:680-687 (Pubitemid 30786248)
26. Melton 3rd LJ, Kan SH, Frye MA, et al. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989;129:1000-1011
27. Melton 3rd LJ, Lane AW, Cooper C, et al. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113-119
28. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-1018 (Pubitemid 26200053)
29. Jones G, White C, Nguyen T, et al. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996;6:233-239 (Pubitemid 26171277)
30. Spector TD, McCloskey EV, Doyle DV, et al. Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: the Chingford Study. J Bone Miner Res 1993;8:817-822 (Pubitemid 23191635)
31. Ross PD, Fujiwara S, Huang C, et al. Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 1995;24:1171-1177 (Pubitemid 26025028)
32. Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-923
33. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999;14:821-828 (Pubitemid 29210609)
34. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-739 (Pubitemid 30174026)
35. Kanis JA, Johnell O, de Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-382 (Pubitemid 38953182)
36. Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 2007;18:761-770 (Pubitemid 46684783)
37. Genant H, Siris E, Crans GG, et al. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 2005;37:170-174 (Pubitemid 40962423)
38. Crans GG, Genant HK, Krege JH. Prognostic utility of a semiquantitative spinal deformity index. Bone 2005;37:175-179 (Pubitemid 40962424)
39. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-532 (Pubitemid 37222378)
40. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003;88:542-549 (Pubitemid 36207787)
41. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation, 2008
42. Lewiecki EM, Laster AJ. Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2006;91:4215-4222 (Pubitemid 44833387)
43. Schousboe JT, Vokes T, Broy SB, et al. Vertebral fracture assessment: the 2007 ISCD official positions. J Clin Densitom 2008;11:92-108
44. Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005;90:1583-1587 (Pubitemid 40464022)